

PEER-REVIEW REPORT

Name of journal: *World Journal of Clinical Cases*

Manuscript NO: 74756

Title: A case report of IgG4 associated autoimmune cholangitis and pancreatitis following the administration of nivolumab.

Provenance and peer review: Unsolicited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 05078461

Position: Peer Reviewer

Academic degree: Doctor, MD

Professional title: Attending Doctor, Chief Doctor, Doctor, Surgeon, Surgical Oncologist, Teacher

Reviewer's Country/Territory: China

Author's Country/Territory: United States

Manuscript submission date: 2022-01-05

Reviewer chosen by: AI Technique

Reviewer accepted review: 2022-02-08 02:04

Reviewer performed review: 2022-02-10 03:05

Review time: 2 Days and 1 Hour

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection

Re-review	[<input checked="" type="checkbox"/>] Yes [<input type="checkbox"/>] No
Peer-reviewer statements	Peer-Review: [<input checked="" type="checkbox"/>] Anonymous [<input type="checkbox"/>] Onymous Conflicts-of-Interest: [<input type="checkbox"/>] Yes [<input checked="" type="checkbox"/>] No

SPECIFIC COMMENTS TO AUTHORS

This is a very meaningful clinical case. There are two problems in the manuscript and it is suggested to modify it: (1) The abbreviations should be consistent from beginning to end, as far as immune checkpoint inhibitors are concerned, there is a mixed use of "ICPI" and "ICI" in the discussion part; (2) The discussion part was not organized well to fully discuss the possible reasons for the IgG4 related pancreatitis and cholangitis caused by nivolumab, and the description of relevant literature is also not comprehensive.

PEER-REVIEW REPORT

Name of journal: *World Journal of Clinical Cases*

Manuscript NO: 74756

Title: A case report of IgG4 associated autoimmune cholangitis and pancreatitis following the administration of nivolumab.

Provenance and peer review: Unsolicited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 06139999

Position: Peer Reviewer

Academic degree: MD, PhD

Professional title: Associate Chief Physician, Surgeon

Reviewer's Country/Territory: China

Author's Country/Territory: United States

Manuscript submission date: 2022-01-05

Reviewer chosen by: AI Technique

Reviewer accepted review: 2022-02-04 07:42

Reviewer performed review: 2022-02-10 03:55

Review time: 5 Days and 20 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input checked="" type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No

Peer-reviewer statements	Peer-Review: [<input checked="" type="radio"/>] Anonymous [<input type="radio"/>] Onymous Conflicts-of-Interest: [<input type="radio"/>] Yes [<input checked="" type="radio"/>] No
-------------------------------------	---

SPECIFIC COMMENTS TO AUTHORS

It is an interesting case. Several questions for the authors: 1. I would like to suggest the authors to revise the title, it is too complex. "A case report of IgG4 associated autoimmune cholangitis and pancreatitis followed by nivolumab" is enough, real, and easy to understand. It is not a good idea in the title to illustrate an unclear mechanism. 2. Please clarify whether the lesion was not related to HIV? 3. What is the potential mechanism of nivolumab led to IgG4 associated autoimmune cholangitis and pancreatitis, or have you seen other drugs induced IgG4 associated autoimmune cholangitis in literature? Please specify. 4. Did you have any consultation or MDT from the department of rheumatology and immunology since it is an autoimmune disease. If yes, what were their advices for the diagnosis and treatment? Please specify.